Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase

National Committee for Clinical Laboratory Standards

Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736

Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study

Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496

Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality

Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286

Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences

Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784

Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States

Ostrosky‐Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N. E., Kauffman, C. A., Cleary, J. D., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 494

Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates

Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis

Laverdière, M., LALONDE, R. G., Baril, J.-G., Sheppard, D. C., Park, S., & Perlin, D. S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl022 · Cited by 192

Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin Susceptibility

Katiyar, S. K., Pfaller, M. A., & Edlind, T. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00349-06 · Cited by 189

Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?

Charlier, C., Hart, E. J., Lefort, A., Ribaud, P., Dromer, F., Denning, D. W., & Lortholary, O. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki473 · Cited by 187

In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole

Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.11.5425-5427.2005 · Cited by 161

Resistance to echinocandin-class antifungal drugs.

Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512

Antifungal Resistance and New Strategies to Control Fungal Infections

Vandeputte, P., Ferrari, S., & Coste, A. T. (2011) · International Journal of Microbiology · doi:10.1155/2012/713687 · Cited by 531

Candidiasis and Mechanisms of Antifungal Resistance

Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020) · Antibiotics · doi:10.3390/antibiotics9060312 · Cited by 474

Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins

Walker, L. A., Munro, C. A., de Bruijn, I., Lenardon, M. D., McKinnon, A., & Gow, N. A. R. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000040 · Cited by 445

Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents

Spampinato, C., & Leonardi, D. (2013) · BioMed Research International · doi:10.1155/2013/204237 · Cited by 411

In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance

Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01901-07 · Cited by 391

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

Pfaller, M. A., Diekema, D. J., Andes, D. R., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M. R., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 340

Mechanisms of echinocandin antifungal drug resistance

Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313

Current Perspectives on Echinocandin Class Drugs

Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274

Candida krusei , a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005

Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Nagy, E., Dobiášová, S., Rinaldi, M. G., Barton, R., Veselov, A. V., & the Global Antifungal Surveillance Group (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01915-07 · Cited by 276

Fungal echinocandin resistance

Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267

Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans : Implications for Interpretive Breakpoints

Garcia-Effron, G., Park, S., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01162-08 · Cited by 256

Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints

Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250

Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo

Lee, K. K., MacCallum, D. M., Jacobsen, M. D., Walker, L. A., Odds, F. C., Gow, N. A. R., & Munro, C. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00683-11 · Cited by 209

Breakthrough invasive candidiasis in patients on micafungin.

Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S., & Alexander, B. D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02390-09 · Cited by 196

Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species

Czajka, K. M., Venkataraman, K., Brabant-Kirwan, D., Santi, S. A., Verschoor, C. P., Appanna, V. D., Singh, R. I., Saunders, D., & Tharmalingam, S. (2023) · Cells · doi:10.3390/cells12222655 · Cited by 207

Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection

Thompson, G. R., Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S., & Patterson, T. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00473-08 · Cited by 159

Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature

Kofla, G., & Ruhnke, M. (2011) · European Journal of Medical Research · doi:10.1186/2047-783x-16-4-159 · Cited by 153

Fks1 and Fks2 Are Functionally Redundant but Differentially Regulated in Candida glabrata: Implications for Echinocandin Resistance

Katiyar, S. K., Alastruey-Izquierdo, A., Healey, K. R., Johnson, M. E., Perlin, D. S., & Edlind, T. D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00813-12 · Cited by 148

Increasing incidence of Candida parapsilosis candidemia with caspofungin usage.

Forrest, G. N., Weekes, E., & Johnson, J. K. (2008) · Journal of Infection · doi:10.1016/j.jinf.2007.10.014 · Cited by 144

Mecanismos de resistencia a los antifúngicos: levaduras y hongos filamentosos

Espinel‐Ingroff, A. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70027-5 · Cited by 141

New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance

Fera, M. T., Camera, E. L., & Sarro, A. D. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.67 · Cited by 136

Mutations in the fks1 Gene in Candida albicans , C. tropicalis , and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing

Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., & Dannaoui, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00088-08 · Cited by 132

Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins

García‐Effrón, G. (2020) · Journal of Fungi · doi:10.3390/jof6040262 · Cited by 135

Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies

García‐Effrón, G., Kontoyiannis, D. P., Lewis, R. E., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00802-08 · Cited by 129

Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species

Pfaller, M. A., Castanheira, M., Diekema, D. J., Messer, S. A., Moet, G. J., & Jones, R. N. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02445-09 · Cited by 127

Antifungal drug resistance mechanisms

Pemán, J., Cantón, E., & Espinel‐Ingroff, A. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.18 · Cited by 121

Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment

Cleary, J. D., Garcia-Effron, G., Chapman, S. W., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-07 · Cited by 118

A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies

Gamaletsou, M. N., Walsh, T. J., Zaoutis, T., Pagoni, M., Kotsopoulou, M., Voulgarelis, M., Panayiotidis, P., Vassilakopoulos, T., Angelopoulou, M. K., Marangos, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12312 · Cited by 112

Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species

García‐Effrón, G., Chua, D. J., Tomada, J. R. T., DiPersio, J. R., Perlin, D. S., Ghannoum, M. A., & Bonilla, H. F. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00998-09 · Cited by 104

Review on Current Status of Echinocandins Use

Mroczyńska, M., & Brillowska‐Dąbrowska, A. (2020) · Antibiotics · doi:10.3390/antibiotics9050227 · Cited by 113

Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management

Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99

Changes in Cell Wall Synthesis and Ultrastructure during Paradoxical Growth Effect of Caspofungin on Four Different Candida Species

Bizerra, F. C., Melo, A. S. D. A., Katchburian, E., Freymüller, E. H., Straus, A. H., Takahashi, H. K., & Colombo, A. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00633-10 · Cited by 91

Antifungal drug resistance: do molecular methods provide a way forward?

Perlin, D. S. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283321ce5 · Cited by 89

Acquired multidrug antifungal resistance in Candida lusitaniae during therapy

Asner, S. A., Giulieri, S., Diezi, M., Marchetti, O., & Sanglard, D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02204-15 · Cited by 82

Clinical perspectives on echinocandin resistance among Candida species

Shields, R. K., Nguyen, M. H., & Clancy, C. J. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000215 · Cited by 78

Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy

Forastiero, A., Garcia-Gil, V., Rivero-Menéndez, O., Garcia‐Rubio, R., Monteiro, M. C., Alastruey‐Izquierdo, A., Jordán, R., Agorio, I., & Mellado, E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01005-15 · Cited by 70

Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Panel for Antifungal Susceptibility Testing of the Echinocandins Anidulafungin, Caspofungin, and Micafungin

Pfaller, M. A., Chaturvedi, V. P., Diekema, D. J., Ghannoum, M. A., Holliday, N. M., Killian, S. B., Knapp, C. C., Messer, S. A., Miskov, A., & Ramani, R. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00493-08 · Cited by 68

Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review

Sun, H., & Singh, N. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.020 · Cited by 66

Role for Fks1 in the Intrinsic Echinocandin Resistance of Fusarium solani as Evidenced by Hybrid Expression in Saccharomyces cerevisiae

Katiyar, S. K., & Edlind, T. D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00020-09 · Cited by 69

Echinocandin pharmacodynamics: review and clinical implications

Pound, M. W., Townsend, M. L., & Drew, R. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq081 · Cited by 71

The value of amphotericin B in the treatment of invasive fungal infections

Klepser, M. E. (2010) · Journal of Critical Care · doi:10.1016/j.jcrc.2010.08.005 · Cited by 64

Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes

Song, J., & Stevens, D. A. (2015) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2015.1068271 · Cited by 62

Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Candida Species to Anidulafungin, Caspofungin, and Micafungin

Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02120-10 · Cited by 59

Genetic basis of antifungal drug resistance

Marie, C. S., & White, T. C. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0021-y · Cited by 61

Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit

Ghannoum, M. A., Chen, A. W., Buhari, M. A., Chandra, J., Mukherjee, P. K., Baxa, D. M., Golembieski, A., & Vázquez, J. A. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02660.x · Cited by 55

La pared celular de los hongos y el mecanismo de acción de la anidulafungina

Pontón, J. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70024-x · Cited by 53

Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicans

Wiederhold, N. P., Grabinski, J. L., García‐Effrón, G., Perlin, D. S., & Lee, S. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00959-08 · Cited by 51

Recent Advances in Antifungal Prevention and Treatment

Groll, A. H., & Tragiannidis, A. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.03.003 · Cited by 48

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

Bader, J. C., Lakota, E. A., Flanagan, S., Ong, V. S., Sandison, T., Rubino, C. M., Bhavnani, S. M., & Ambrose, P. G. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02614-17 · Cited by 44

Candida krusei: biotechnological potentials and concerns about its safety

Yadav, J. S. S., Bezawada, J., Yan, S., Tyagi, R. D., & Surampalli, R. Y. (2012) · Canadian Journal of Microbiology · doi:10.1139/w2012-077 · Cited by 44

Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi

Guarro, J. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr143 · Cited by 42

Antifungals in the ICU

Playford, E. G., Eggimann, P., & Calandra, T. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283177967 · Cited by 42

In VivoandIn VitroAcquisition of Resistance to Voriconazole by Candida krusei

Ricardo, E., Miranda, I. M., Faria‐Ramos, I., Silva, R. M., Rodrigues, A. G., & Pina‐Vaz, C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02603-14 · Cited by 40

Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.

Desnos-Ollivier, M., Moquet, O., Chouaki, T., Guérin, A.-M., & Dromer, F. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00325-11 · Cited by 37

Raman Spectroscopy of Oral Candida Species: Molecular-Scale Analyses, Chemometrics, and Barcode Identification

Pezzotti, G., Kobara, M., Nakaya, T., Imamura, H., Miyamoto, N., Adachi, T., Yamamoto, T., Kanamura, N., Ohgitani, E., Marin, E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105359 · Cited by 39

Antifungal Susceptibility Profiles of 1698 Yeast Reference Strains Revealing Potential Emerging Human Pathogens

Desnos‐Ollivier, M., Robert, V., Raoux‐Barbot, D., Groenewald, M., & Dromer, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032278 · Cited by 37

Targeting Candida spp. to develop antifungal agents

Salci, T. P., Negri, M., Abadio, A. K. R., Svidzinski, T. I. E., & Kioshima, É. S. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.003 · Cited by 35

Detection of Caspofungin Resistance in Candida spp. by Etest

Desnos‐Ollivier, M., Dromer, F., & Dannaoui, É. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00053-08 · Cited by 35

Posaconazole: A New Agent for the Prevention and Management of Severe, Refractory or Invasive Fungal Infections

Page, A. V., & Liles, W. C. (2008) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2008/825901 · Cited by 29

Role of FKS Gene in the Susceptibility of Pathogenic Fungi to Echinocandins

Hori, Y., & Shibuya, K. (2018) · Medical Mycology Journal · doi:10.3314/mmj.18.004 · Cited by 28

Echinocandin Failure Case Due to a Previously Unreported FKS1 Mutation in Candida krusei

Hare, R. K., Justesen, U. S., Rewes, A., Perlin, D. S., & Arendrup, M. C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02367-14 · Cited by 28

Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies

Marr, K. A. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328307c7d9 · Cited by 28

Antifungal resistance does not necessarily affect Candida glabrata fitness

Borghi, E., Andreoni, S., Cirasola, D., Ricucci, V., Sciota, R., & Morace, G. (2014) · Journal of Chemotherapy · doi:10.1179/1973947813y.0000000100 · Cited by 25

Treatment of invasive candidiasis with echinocandins

Glöckner, A., Steinbach, A., Vehreschild, J. J., & Cornely, O. A. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01645.x · Cited by 22

Prevalence of Antifungal Resistance, Genetic Basis of Acquired Azole and Echinocandin Resistance, and Genotyping of Candida krusei Recovered from an International Collection

Khalifa, H. O., Hubka, V., Watanabe, A., Nagi, M., Miyazaki, Y., Yaguchi, T., & Kamei, K. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01856-21 · Cited by 22

Fluconazole and echinocandin resistance of Candida species in invasive candidiasis at a university hospital during pre-COVID-19 and the COVID-19 outbreak

Szekely, J., Rakchang, W., Rattanaphan, P., & Kositpantawong, N. (2023) · Epidemiology and Infection · doi:10.1017/s0950268823001346 · Cited by 24

Comparison of Anidulafungin MICs Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 Document) and Etest for Candida Species Isolates

Espinel‐Ingroff, A., Cantón, R., Pemán, J., & Martín‐Mazuelos, E. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01324-09 · Cited by 21

Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains

Denardi, L. B., Keller, J. T., Oliveira, V., Mario, D. A. N., Santúrio, J. M., & Alves, S. H. (2017) · Mycopathologia · doi:10.1007/s11046-017-0141-9 · Cited by 21

Antimycotic Drugs and their Mechanisms of Resistance to Candida Species

Dahiya, S., Sharma, N., Punia, A., Choudhary, P., Gulia, P., Parmar, V. S., & Chhillar, A. K. (2021) · Current Drug Targets · doi:10.2174/1389450122666210719124143 · Cited by 19

Phenotypic Analysis of a Family of Transcriptional Regulators, the Zinc Cluster Proteins, in the Human Fungal Pathogen Candida glabrata

Klimova, N. G., Yeung, R., Kachurina, N., & Turcotte, B. (2014) · G3 Genes Genomes Genetics · doi:10.1534/g3.113.010199 · Cited by 17

Sequencing of FKS Hot Spot 1 from Saprochaete capitata To Search for a Relationship to Reduced Echinocandin Susceptibility

Arrieta-Aguirre, I., Menéndez-Manjón, P., Cuétara, M. S., Fernandez-de-Larrinoa, Í., García‐Ruiz, J. C., & Moragues, M. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01246-17 · Cited by 13

Micafungin in the treatment of invasive candidiasis and invasive aspergillosis

Wiederhold, N. P., Cota, & Frei, C. R. (2009) · Infection and Drug Resistance · doi:10.2147/idr.s3864 · Cited by 13

Approaches to serious methicillin-resistant Staphylococcus aureus infections with decreased susceptibility to vancomycin: clinical significance and options for management

Lewis, J. S., & Ellis, M. W. (2008) · Current Opinion in Internal Medicine · doi:10.1097/qco.0b013e3282f1beb8 · Cited by 13

Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans

Akins, R. A., & Sobel, J. D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-180-2_29 · Cited by 12

Anidulafungin: A Novel Echinocandin for Candida Infections

de la Torre, P., Meyer, D. K., & Reboli, A. C. (2008) · Future Microbiology · doi:10.2217/17460913.3.6.593 · Cited by 12

Micafungin for the prophylaxis and treatment ofCandidainfections

Fritz, J. M., Brielmaier, B. D., & Dubberke, E. R. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.2.153 · Cited by 12

In vitro activity of echinocandins against non-Candida albicans: Is echinocandin antifungal activity the same?

Espinel‐Ingroff, A., & Cantón, E. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70002-7 · Cited by 11

Genomic and probiotic characterization of SJP-SNU strain of Pichia kudriavzevii

Hong, S.-M., Kwon, H., Park, S.-J., Seong, W.-J., Kim, I., & Kim, J. (2018) · AMB Express · doi:10.1186/s13568-018-0609-0 · Cited by 13

Existing and emerging therapies for the treatment of invasive candidiasis and candidemia

Bels, D. D., Maillart, E., Françoise Van Bambeke, A., Redant, S., & Honoré, P. M. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2142207 · Cited by 12

Activity of Anidulafungin in a Murine Model of Candida krusei Infection: Evaluation of Mortality and Disease Burden by Quantitative Tissue Cultures and Measurement of Serum (1,3)-β- d -Glucan Levels

Ostrosky‐Zeichner, L., Paetznick, V. L., Rodriguez, J., Chen, E., & Sheehan, D. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00955-08 · Cited by 11

Actividad antifúngica in vitro de la micafungina

Quindós, G., Eraso, E., Carrillo‐Muñoz, A. J., Cantón, E., & Pemán, J. (2009) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(09)70006-3 · Cited by 9

Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida spp. isolates

Espinel‐Ingroff, A., Cantón, E., Peláez, T., & Pemán, J. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.12.010 · Cited by 9

Influence of Serum and Albumin on Echinocandin In Vitro Potency and Pharmacodynamics

Nasar, A., Ryan, L., Frei, C. R., Cota, J. M., & Wiederhold, N. P. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0136-z · Cited by 9

Genomic analyses reveal high diversity and rapid evolution of Pichia kudriavzevii within a neonatal intensive care unit in Delhi, India

Jain, K., Wang, Y., Jain, P., Kalita, B., Shivarathri, R., Chauhan, M., Kaur, H., Chauhan, N., Xu, J., & Chowdhary, A. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01709-24 · Cited by 8

Actividad antifúngica in vitro de la anidulafungina

Quindós, G., & Eraso, E. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70025-1 · Cited by 8

Analysis of molecular resistance to azole and echinocandin in Candida species in patients with vulvovaginal candidiasis

Lotfali, E., Erami, M., Fattahi, A., Nemati, H., Ghasemi, Z., & Mahdavi, E. (2022) · Current Medical Mycology · doi:10.18502/cmm.8.2.10326 · Cited by 8

Anidulafungin and its role in candida infections

Cappelletty, D. M. (2009) · Infection and Drug Resistance · doi:10.2147/idr.s4796 · Cited by 7

Evidencias científicas que respaldan el uso de micafungina en el tratamiento de la candidiasis invasora

Montejo, M., & Quindós, G. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70004-0 · Cited by 6

Antifungal drug resistance: Significance and mechanisms

Dharmaiah, S., Sherif, R., & Mukherjee, P. K. (2019) · CRC Press eBooks · doi:10.1201/9780429402012-4 · Cited by 6

The Role of Resistance in Candida Infections: Epidemiology and Treatment

Sobel, J. D., & Akins, R. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_18 · Cited by 6

Antifungal Resistance: Cellular and Molecular Mechanisms

Araújo, R., & Espinel‐Ingroff, A. (2010) · Springer eBooks · doi:10.1007/978-3-642-12173-9_7 · Cited by 5

Actividad in vitro de anidulafungina. Comparación con la actividad de otras equinocandinas

Martín‐Mazuelos, E., & Rodrı́guez-Tudela, J. L. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(08)76587-x · Cited by 4

Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins

Pfaller, M. A., Diekema, D. J., Castanheira, M., & Jones, R. N. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0053-y · Cited by 4

Anidulafungin: advantage for the newcomer?

Rüping, M. J. G. T., Vehreschild, J. J., Farowski, F., & Cornely, O. A. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.2.207 · Cited by 4

Les pompes à efflux en mycologie médicale : mécanismes moléculaires et perspectives thérapeutiques

Kouidhi, B., Gaied, M. B., Mhadhebi, L., Bakhrouf, A., & Bouraoui, A. (2010) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2010.07.007 · Cited by 4

ClinicalCandida kruseiisolates remain susceptible during extensive exposure to antifungal drugs

Hautala, T., Kakko, S., Siitonen, T., Säily, M., Koistinen, P., & Koskela, M. (2010) · Medical Mycology · doi:10.3109/13693780902725276 · Cited by 4

Antifungal Drug Resistance in Developing Countries

Perlin, D. S. (2009) · Springer eBooks · doi:10.1007/978-0-387-89370-9_9 · Cited by 4

Presence of L701 M mutation in the FKS1 gene of echinocandin-susceptible Candida krusei isolates

Lallitto, F., Prigitano, A., Mangione, F., Piralla, A., Tamarozzi, F., Marone, P., & Cavanna, C. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.07.005 · Cited by 3

The Role of Resistance in Candida Infections: Epidemiology and Treatment

Sobel, J. D., & Akins, R. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-595-8_18 · Cited by 2

Acquired echinocandin resistance in a Candida krusei blood isolate confirmed by mutations in the fks1 gene.

Prigitano, A., Esposito, M. C., Cogliati, M., Pitzurra, L., Santamaria, C., & Tortorano, A. M. (2014) · PubMed · Cited by 8

Presence of L701 M mutation in the FKS1 gene of echinocandin-susceptible Candida krusei isolates

Lallitto, F., Prigitano, A., Mangione, F., Piralla, A., Tamarozzi, F., Marone, P., & Cavanna, C. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.07.005 · Cited by 3

Novel FKS1 and FKS2 modifications in a high-level echinocandin resistant clinical isolate of Candida glabrata

Hou, X., Healey, K. R., Shor, E., Kordalewska, M., Ortigosa, C. J., Paderu, P., Xiao, M., Wang, H., Zhao, Y., Lin, L.-Y., et al. (2019) · Figshare · doi:10.6084/m9.figshare.10289375

Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy

Forastiero, A., Garcia-Gil, V., Rivero-Menéndez, O., Garcia‐Rubio, R., Monteiro, M. C., Alastruey‐Izquierdo, A., Jordán, R., Agorio, I., & Mellado, E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01005-15 · Cited by 70

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β- d -Glucan Synthase: Implication for the Existing Susceptibility Breakpoint

Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323